VM:CC - Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch

(TheNewswire)

Calgary, Alberta, Canada – April 1, 2025 – TheNewswire - VoyageurPharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF)(" Voyageur " or the " Company ") is pleased to announce thesuccessful completion of a key phase in human testing of its HealthCanada-licensed barium contrast media product suite. This milestonepaves the way for Voyageur’s upcoming product launch across theCandain market.

A total of 24 test subjects participated in the phaseone program, which involved oral administration of Voyageurs contrastagents, followed by diagnostic imaging procedures. Four ofVoyageur’s licensed barium contrast media products (SmoothLD®,SmoothHD®, VisionHD®, and VisionLD®) were used in theseevaluations. The images generated are currently undergoing finalanalysis by Voyageurs team of radiology experts and its ScientificAdvisory Board, who are assessing both quantitative and qualitativeimaging performance, including diagnostic clarity and overall imagequality.

Final performance review is expected to be completedwithin 30 days. Following this, Voyageur will begin market testing andinitial commercial sales in Canada. Discussions are also underway withinternational distribution partners in jurisdictions that recognizeHealth Canada licensed medical products.

Upon Canadian market entry, Voyageur will initiatephase two testing to support FDA licensing under the 505(2)(b)pathway. This next phase will generate clinical and operational datafocused on key performance indicators, including safety, efficacy, pharmacokinetic, pharmacodynamics,regulatory compliance and market readiness.

Voyageur’s proprietary contrast media formulationsare engineered to deliver superior image clarity for gastrointestinalradiographic procedures across adult and pediatric populations. TheCompany’s focus on innovation, image quality and patient safetypositions it as a key player in the evolving global contrast mediamarket.

Diagnostic centres interested in integratingVoyageur’s next generation barium contrast media products into theirimaging programs are encouraged to contact Ethan Mohan at Ethan@Vpharma.ca .

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium and iodine ActivePharmaceutical Ingredients (API) that offer high-performance andcost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium and iodine contrast markets,Voyageur aims to become a key player by producing its own barium andiodine. In addition, Voyageur is pursuing the development of new endofullerene drugs.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada thereby ensuring the validation of itsproducts by regulatory agencies worldwide. As Voyageur solidifies itspresence in the market, it plans to transition into a high-margindomestic manufacturer of radiology drugs.

Voyageur is committed to sustainability andenvironmental stewardship. Voyageur envisions a future where reducingcarbon emissions is the norm, and to achieve this, it will buildstate-of-the-art carbon-capture infrastructure utilising the Rain Cage EDEN TM system . Byinvesting in carbon capture energy sources and sustainablemanufacturing practices, Voyageur aims to generate revenue from carboncaptured “advanced carbon production”. Voyageur's unwaveringcommitment to the environment sets it apart as a pioneer in theindustry.

At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project.Currently, the worlds pharmaceutical barium sulphate is almostentirely synthetically produced resulting in a less effective imagingquality product. Voyageur’s Frances Creek resource boasts a rare andexceptional grade mineral suitable for the pharmaceutical marketplacethat Voyageur believes will replace the current synthetic productswith higher quality imaging products.

Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to final production, Voyageur believes it can ensurequality and cost efficiency. With its approach, it embodies the mottoof " From the Earth to theBottle ," highlighting Voyageur's commitmentto responsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

Thisnews release may contain certain forward-looking information andstatements, including without limitation, statements pertaining to:the successful completion of clinical testing; Canadian, FDA and otherregulatory approvals; and the effectiveness, efficiency and marketacceptance of the five barium contrast drugs and one gas agent. Allstatements included herein, other than statements of historical fact,are forward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR+ website at www.sedarplus.ca. Voyageur does not undertake toupdate any forward-looking information except in accordance withapplicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.